Somatuline LA (lanreotide suspension intramuscular)

News alerts, weekly reports and conference planners

Company:

Ipsen, Teijin

Drug class:

Somatostatin analogue

‹

›

4ms

Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula (clinicaltrials.gov)

P3, N=274, Recruiting, SWOG Cancer Research Network | Not yet recruiting --> Recruiting

4 months ago

Enrollment open

lanreotide prolonged-release subcutaneous • Somatuline LA (lanreotide suspension intramuscular)

11ms

Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula (clinicaltrials.gov)

P3, N=274, Not yet recruiting, SWOG Cancer Research Network

11 months ago

New P3 trial

lanreotide prolonged-release subcutaneous • Somatuline LA (lanreotide suspension intramuscular)

over4years

A trial to assess efficacy and safety of octreotide subcutaneous depot in patients with GEP-NET (clinicaltrialsregister.eu)

P3, N=302, Ongoing, Camurus AB

over 4 years ago

New P3 trial

SSTR (Somatostatin Receptor)

SSTR positive

lanreotide prolonged-release subcutaneous • Oclaiz (octreotide subcutaneous depot) • Somatuline LA (lanreotide suspension intramuscular) • octreotide acetate

almost5years

A clinical trial aiming to assess the safety and activity of the combination of cabozantinib plus lanreotide in gastroenteropancreatic (GEP) and thoracic neuroendocrine tumor (NET) Studio clinico finalizzato a valutare il profilo di sicurezza e di attività di cabozantinib in combinazione a lanreotide in tumori neuroendocrini (NET) gastroenteropancreatici (GEP) e toracici (clinicaltrialsregister.eu)

P2, N=69, Ongoing, FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI"

almost 5 years ago

Clinical • New P2 trial

PIAS4 (Protein Inhibitor Of Activated STAT 4)

Cabometyx (cabozantinib tablet) • lanreotide prolonged-release subcutaneous • Somatuline LA (lanreotide suspension intramuscular)